Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Introduction: Chronic obstructive pulmonary disease (COPD) is a serious global healthcare problem. WHO predicts COPD as a leading cause of death by 2030. It is commonly diagnosed via spirometry also known as Pulmonary Function Test (PFT). Long Acting Beta Agonist/Long Acting Muscarinic Antagonist (LABA/LAMA) fixed dose combinations (FDC) remains the cornerstone in treatment of COPD. A FDC of IND/GLY was recently approved for COPD. This FDC induces dual bronchodilation.